Rhythm Pharmaceuticals (RYTM) PT Raised to $92 at Canaccord Genuity

Canaccord Genuity analyst Whitney Ijem raised the price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $92.00 (from $81.00) while maintaining a Buy rating.

The analyst commented: "We are updating our model on the back of positive setmelanotide Ph3 data for acquired HO this morning (our thoughts here). Based on the primary endpoint result of -19.8% placebo adjusted BMI reduction from baseline (P<0.0001), we are increasing our POS in both the US and Europe to 100% (vs. 80% prev). We are conservatively maintaining a 70% POS in Japan for now, but see additional upside potential with anticipated data release in 1Q26. The net result is an increase in our YE25 PT to $92 (vs. $81 prev). Maintain BUY."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)
• Stripe, Advent In Talks To Buy Paypal - WSJ